![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00239902 |
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
Condition | Intervention | Phase |
---|---|---|
Renal Transplantation |
Drug: FTY720 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Two-Year Extension of a One-Year, Multicenter, Randomized, Partially-Blinded Study of the Safety and Efficacy of FTY720 Combined With Corticosteroids and Full or Reduced-Dose Cyclosporine, USP [Modified] (Novartis Brand) in De Novo Adult Renal Transplant Recipients |
Estimated Enrollment: | 396 |
Study Start Date: | May 2002 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined exclusion criteria may apply.
Study ID Numbers: | CFTY720A0121E1 |
Study First Received: | October 13, 2005 |
Last Updated: | May 31, 2006 |
ClinicalTrials.gov Identifier: | NCT00239902 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Transplantation, kidney, and organ transplantation |
Cyclosporine Immunologic Factors Fingolimod Immunosuppressive Agents Cyclosporins |
Immunologic Factors Fingolimod Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |